Infineum International Limited

Gist-brocades N.v.

Shell Internationale Research Maatschappij, B.v.

Dsm N.v.

Archimedes Development Limited

Koninklijke Gist-brocades N.v.

Dsm Gist Holding B.v.

Peter D Watts

Peter J Dowding

Richard D Bertram

Arthur F Marx

Gareth T Phillips

Hein Simon Koger

Mauro A Bertola

Brian W Robertson

Wilhelmus J Quax

Laura Gregory

Cornelis J Van Der Laken

Terence Garner

Richard David Bertram

Peter John Dowding

Jacob I Emert

Philip Skinner

Joseph P Hartley

Jeremy Roger Spencer

Jonathan David Castile

Stephen Arrowsmith

Laura Kosidowski

Daniel Whyte

Terry Garner

Robert Hough

Luciana Angonesi

Hein S Koger

Alan Smith

Joseph Peter Hartley

A lubricant additive concentrate containing 30 to 80 mass % oil of lubricating viscosity and from 20 to 70 mass % of additive; wherein from 30 to 90 mass % of the additive is (i) hybrid overbased colloidal detergent derived from sulfonate surfactant and hydroxybenzoate surfactant; and (ii) polyalkenyl succinimide dispersant derived from a polyalkene having a number average molecular weight (M) of from 1300 to 2500 daltons, and wherein the mass ratio of polyalkenyl succinimide dispersant (ii) to hybrid overbased colloidal detergent (i) in the lubricant additive is from 25:1 to 1:1.

Additive concentrates for the formulation of lubricating oil compositions

A lubricating oil composition comprising a Group II basestock and a neutral or overbased metal hydrocarbyl-substituted hydroxybenzoate detergent having a basicity index of less than 2.

Lubricating oil composition

Trunk piston marine engine lubrication, when the engine is fueled by heavy fuel oil, is effected by a composition comprising a major amount of an oil of lubricating viscosity containing at least 50 mass % of a Group II basestock, and respective minor amounts of an overbased metal hydrocarbyl-substituted hydroxybenzoate detergent other than such a detergent having a basicity index of less than two and a degree of carbonation of 80% or greater and 5 to 500 mass %, based on the mass of the detergent, of an oil-soluble alkyl-substituted phenol other than a hindered phenol. Asphaltene precipitation in the lubricant, caused by the presence of contaminant heavy fuel oil, is prevented or inhibited.

Marine engine lubrication

A detergent including one or more neutral or overbased alkaline earth metal Cto Chydrocarbyl substituted hydroxybenzoates, in which:

[object Object]

A method of reducing asphaltene precipitation or 'black paint' in an engine is disclosed. The method includes the step of lubricating the engine with a lubricating oil composition comprising: an oil of lubricating viscosity in a major amount; and, a salicylate detergent system in a minor amount comprising one or more neutral or overbased alkaline earth metal Chydrocarbyl substituted salicylates.

Method of reducing asphaltene precipitation in an engine utilizing a C22 hydrocarbyl salicylate

An overbased metal hydrocarbyl-substituted hydroxybenzoate detergent having a basicity index of less than 2 and a degree of carbonation of 80% or greater is disclosed. The overbased metal hydrocarbyl-substituted hydroxybenzoate detergent reduces asphaltene precipitation or 'black paint' in a marine diesel engine.

Detergent

A process for the preparation of a pharmaceutically active compound in a stereospecific form of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, like an alkali metal salt or an alkaline earth metal salt or a pivaloyl ester, wherein R.sub.1 represents an optionally substituted aryl group such as a phenyl or naphthyl group optionally included in a heterocyclic ring system, which is optionally substituted, or represents a heteroaromatic ring system containing in addition to carbon atoms one or more atoms selected from nitrogen, sulphur and oxygen, this ring system being optionally substituted, which comprises subjecting a compound of the formula ##STR2## wherein R.sub.2 is an ester residue and preferably an alkyl group optionally substituted, to the action of a micro-organism having the ability for stereoselective hydrolysis of compound (II) into compound (I), having at least 80% by weight the S-configuration, and if desired converting compound (I) into the pharmaceutically acceptable salt or ester thereof.

Microbial purified esterases

A process for the preparation of metoprolol in a stereospecific form or a non-toxic, pharmaceutically acceptable acid addition salt thereof and/or a stereospecific form of 4-(2-methoxyethyl)-phenyl glycidyl ether which comprises subjecting 4-(2-methoxyethyl)-phenyl allyl ether to the action of a microorganism having the ability for stereoselective epoxidation of 4-(2-methoxyethyl)-phenyl allyl ether into 4-(2-methoxyethyl)-phenyl glycidyl ether having at least 80% by weight the S configuration, at least partly separating 4-(2-methoxyethyl)-phenyl glycidyl ether and/or reacting 4-(2-methoxyethyl)-phenyl glycidyl ether with isopropylamine and at least partly separating metoprolol and/or converting metoprolol into its non-toxic, pharmaceutically acceptable acid addition salt.

Process for producing 4-(2-methoxyethyl)-phenyl-glycidyl ether and/or

A process for the preparation of a pharmaceutically active compound in a stereospecific form of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, like an alkali metal salt or an alkaline earth metal salt or a pivaloyl ester, wherein R.sub.1 represents an optionally substituted aryl group such as a phenyl or naphthyl group optionally included in a heterocyclic ring system, which is optionally substituted, or represents a heteroaromatic ring system containing in addition to carbon atoms one or more atoms selected from nitrogen, sulphur and oxygen, this ring system being optionally substituted, which comprises subjecting a compound of the formula ##STR2## wherein R.sub.1 is an ester residue and preferably an alkyl group optionally substituted, to the action of a micro-organism having the ability for stereoselective hydrolysis of compound (II) into compound (I), having at least 80% by weight the S-configuration, and if desired converting compound (I) into the pharmaceutically acceptable salt or ester thereof.

Process for the preparation of a pharmaceutically active compound in a

Growing community of inventors

Abingdon, United Kingdom

Peter D Watts